Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AEX-2
Therapeutic Area : Sleep
Study Phase : Preclinical
Recipient : NLS Pharmaceutics
Deal Size : Inapplicable
Deal Type : Inapplicable
NLS Announces Preclinical Data for AEX-2 Dual Orexin Agonist
Details : AEX-2 is a potential first-in-class non-sulfonamide dual orexin receptor agonist (DOXA), which is being evaluated for narcolepsy and related neurological disorders.
Product Name : AEX-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2025
Lead Product(s) : AEX-2
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Recipient : NLS Pharmaceutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AEX-2
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : NLS Pharmaceutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
NLS Pharmaceutics Secures Exclusive Global License for Dual Orexin Agonist Platform
Details : The agreement grants NLS global rights to next-gen oral OX1R/OX2R agonists, including AEX-2, tailored for narcolepsy, idiopathic hypersomnia, Parkinson's disease, dementia with Lewy bodies.
Product Name : AEX-2
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 20, 2024
Lead Product(s) : AEX-2
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : NLS Pharmaceutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement